head to RG but put χονδρική in stage 4
μία μετα 2021
Pooled prevalence (PP) of oral cancer in patients with diabetic was 0.25% (95% CI = 0.15-0.39)-250 per 100,000 patients with diabetes mellitus -with a greater chance of oral cancer among patients with diabetes mellitus (OR = 1.41 [95% CI = 1.10-1.81], p = .007). Patients with oral cancer and diabetes mellitus had a higher mortality than controls (HR = 2.09 [95%CI = 1.36-3.22], p = .001). Leukoplakia had a PP = 2.49% (95% CI = 1.14-4.29)-2,490 per 100,000 patients with diabetes mellitus -(OR = 4.34 [95% CI = 1.14-16.55], p = .03). A PP of 2.72 (95% CI = 1.64-4.02) was obtained for oral lichen planus among patients with diabetic -2,720 per 100,000 patients with diabetes mellitus (OR = 1.87 [95% CI = 1.37-2.57], p < .001). A low PP was estimated for erythroplakia (0.02%[95%CI = 0.00-0.12]-20 per 100,000 patients with diabetes mellitus. In conclusion, patients with diabetes mellitus have a higher prevalence and greater chance of oral cancer and OPMD development in comparison with non-diabetic patients. In addition, patients with oral cancer suffering from diabetes mellitus have a higher mortality compared to non-diabetic patients with oral cancer
https://pubmed.ncbi.nlm.nih.gov/31994293/
rev 2016
Recent studies suggest that there is also association between cancer incidence and anti-diabetic medications. It was observed that some medications decrease the risk of carcinogenesis and some increase that risk. The majority of studies concern metformin, a drug of choice in type 2 diabetes mellitus, and its anti-neoplastic and tumor-suppressing activity. The positive effect of metformin was found in numerous researches investigating breast, pancreas, liver, colon, ovaries and prostate tumors.Because a variety of studies have suggested that diabetes mellitus and cancer are frequently coexisting diseases, recently published studies try to explain the influence of diabetes mellitus and anti-diabetic medications on carcinogenesis in different organs.We present the review of the latest studies investigating the association between both diabetes mellitus and anti-diabetic medications and cancer incidence and prognosis.Particularly we highlight the problem of concomitant head and neck cancers in diabetics, rarely analysed and often omitted in studies
https://pubmed.ncbi.nlm.nih.gov/27219686/
rev 20
Obesity and diabetes have both been associated with an increased risk of cancer. In the face of increasing obesity and diabetes rates worldwide, this is a worrying trend for cancer rates. Factors such as hyperinsulinemia, chronic inflammation, antihyperglycemic medications, and shared risk factors have all been identified as potential mechanisms underlying the relationship. The most common obesity- and diabetes-related cancers are endometrial, colorectal, and postmenopausal breast cancers. In this review, we summarize the existing evidence that describes the complex relationship between obesity, diabetes, and cancer, focusing on epidemiological and pathophysiological evidence, and also reviewing the role of antihyperglycemic agents, novel research approaches such as Mendelian Randomization, and the methodological limitations of existing research. In addition, we also describe the bidirectional relationship between diabetes and cancer with a review of the evidence summarizing the risk of diabetes following cancer treatment. We conclude this review by providing clinical implications that are relevant for caring for patients with obesity, diabetes, and cancer and provide recommendations for improving both clinical care and research for patients with these conditions.
https://pubmed.ncbi.nlm.nih.gov/31722374/
Many observations suggest that obesity and diabetes are associated with an increased risk of developing several types of cancers, including liver, pancreatic, endometrial, colorectal, and post-menopausal breast cancer
Epidemiologically, individuals with obesity and diabetes are susceptible to an increased risk as well as a greater mortality rates for several types of cancers, such as endometrial, liver, pancreatic, colorectal, and breast cancer
Growing epidemiological evidence is hinting at a causal link between obesity, diabetes, and cancer
T2DM AND CANCER DEVELOPMENT Diabetes mellitus (DM) is one of the most prevalent chronic metabolic disorder characterized by hyperglycemia [3]. Dysfunction of pancreatic insulin-producing β-cells and insulin resistance mainly leads to hyperglycemia, resulting in increased risk of T2DM development [93]. T2DM is most common form of DM, which accounts for around 90% of all cases of diabetes [93]. T2DM may be associated with increased risk, accelerated progression and greater mortality rates of several types of cancer such as liver, pancreatic, endometrial, colorectal, and breast cancer [3,94,95]. Anti-diabetic drugs, such as metformin, have recently attracted considerable interest and opened a promising avenue of research that has the potential for the treatment of breast and colorectal cancers due to their proposed anti-cancer properties [95-98]. In the following section, we discuss the various mechanism by which metabolic disturbances in T2DM, such as dyslipidemia, hyperinsulinemia, and hyperglycemia, may lead to the development of breast cancer.
CONCLUSIONS The growing prevalence of obesity and diabetes are closely linked to an increased incidence and mortality of many types of cancer [2-4,9,56,94]. The multiple metabolic factors and disorders linking obesity and T2DM with cancer that are broadly discussed in this review may be important for determining the therapeutic potential of cancer treatment. Altered adipose tissue metabolism in obesity results in altered levels of multiple factors, such as hormones, adipokines, inflammatory cytokines, growth factors, enzymes, and free fatty acids to help cancer cells satisfy their metabolic and energy demands [7,13,24]. Adipocytes also acquire phenotypic changes through multiple bioactive factors released by surrounding cancer cells, resulting in significantly increased secretion of many metabolic substrates [30,78,87]. This adipocyte/cancer cell crosstalk within the tumor microenvironment leads to further morphological and functional alterations of both cell types, which is gradually being recognized as an integral part of cancer development and progression. However, many important questions remain regarding the molecular fingerprint and the biological roles of such a crosstalk in promoting cancer development and progression. Therefore, (1) a more in-depth understanding of how adipocytes interact with tumor cells and contribute to cancer development and progression is required; (2) identification of specific targets that can serve as promising avenues to limit tumor proliferation need to be identified; (3) determination of new strategies to block this interaction could be an effective/attractive therapeutic strategy in the treatment of cancers. T2DM is the most common form of diabetes that appears to be associated with an increased risk of several types of cancer due to its associations with multiple metabolic disturbances [94,95]. Various metabolic disturbances involved in the development of diabetes, such as dyslipidemia and hyperinsulinemia, are well established to lead to the development of a cancer-conducive microenvironment. Based on these observations, a series of studies suggest that the use of anti-diabetic drugs, e.g., metformin, may have the potential to reduce the cancer incidence and/or mortality in diabetic patients. Mechanistically, metformin reduces the circulating levels of insulin and IGF-1, thus inhibiting the mTOR pathway and subsequent cancer cell proliferation [128]. Given the potential of metformin for cancer therapy, metformin has attracted increased attention and opened new avenues in cancer treatment due to their proposed anti-cancer properties. In contrast, a recent a population-based cohort study indicated that metformin use was not associated with significantly decreased risk of cancer among patients with diabetes [129-131]. Based on large population-based cohort studies, further insights into the potential utility of metformin will be required to evaluate the effect of metformin therapy in cancer incidence.
https://europepmc.org/article/MED/34847640
Type-2-diabetes (T2D) increases the risk for several cancers and cancer has become the major cause of death of T2D-patients. T2D is causally associated with colorectal, pancreatic, gallbladder, biliary, hepatocellular, gastric, esophageal, oral, breast, endometrial, ovary, kidney and thyroid cancers as well as leukemias. When T2D goes along with tobacco smoking, alcohol use, physical inactivity, excess body weight, poor diet, familial risk or certain chronic infections, the cumulative cancer risk rises, and T2D-patients often suffer from cancer disease at younger age. T2D-patients should be encouraged to join cancer screening programmes even at younger age than the average non-diabetic population.
https://pubmed.ncbi.nlm.nih.gov/34521128/
Peripheral insulin resistance and hyperinsulinemia are the predominant diabetic traits in pancreatic cancer.
The causal relationship between diabetes and pancreatic cancer remains an intriguing but unanswered question. Since diabetes often precedes pancreatic cancer, it is regarded as a potential risk factor for malignancy. On the other hand, there remains the possibility that pancreatic cancer secretes diabetogenic factors. Regardless of how the science ultimately illuminates this issue, there is increasing interest in utilizing screening for diabetes to aid early detection of pancreatic tumor lesions. Therefore, in this issue of Pancreatology and the Web, we explore the topic of diabetes to keep us alert to this very important association, even if we study diseases of the exocrine pancreas
https://pubmed.ncbi.nlm.nih.gov/19299909/
Case presentation: We report the case of a 50-year-old man with a diagnosis of type 2 diabetes mellitus who-despite appropriate pharmacotherapy-developed worsening hyperglycemia. Further investigation revealed the presence of metastatic pancreatic cancer.
Discussion: Although an association between pancreatic cancer and diabetes has been noted widely in the gastroenterology, oncology, and endocrine literature, a paucity of primary care literature on the topic exists. Features of predominant insulin deficiency and new onset of diabetes in a patient without family history of type 2 diabetes should raise suspicion for undetected/early-stage pancreatic cancer.
Conclusions: This case highlights the importance of considering all possible pathophysiologic etiologies when a patient has a new diagnosis of diabetes. Clinicians should consider the possibility of pancreatic cancer in patients with new-onset diabetes mellitus, especially when features not characteristic of type 2 diabetes are present. Understanding the relationship between diabetes and pancreatic cancer has the potential to improve early detection of pancreatic cancer and can provide an opportunity for early treatment and improved survival.
https://pubmed.ncbi.nlm.nih.gov/30407768/
Diabetic mastopathy is a recently described pathological entity. Little is known about this benign condition. It usually occurs in young patients with type 1 diabetes, or having an autoimmune disorders. Clinically, this mastopathy simulates a breast cancer. Graphic tests are not very informative. The diagnosis is histological. Through a case of diabetic mastopathy occurring in a patient with diabetes on insulin for 16 years and carries multiple degenerative complications, we recall the clinical, radiological and outcome of this disease.
https://pubmed.ncbi.nlm.nih.gov/20971584/
Diabetes mellitus, commonly known as diabetes, and cancer are two of the most common diseases plaguing the world today. According to the Centers for Disease Control and Prevention (CDC), there are currently more than 20 million people with diabetes in the United States [1]. According to the International Agency for Research on Cancer (IARC), there were around 18 million people diagnosed with cancer, with approximately ten million deaths globally in 2018 [2]. Given the prevalence and deadliness of diabetes and cancer, these two diseases have long been the focus of many researchers with the goal of improving treatment outcomes. While diabetes and cancer may seem to be two very different diseases at first glance, they share several similarities, especially regarding their metabolic characteristics. This chapter discusses the similarities and relationships between the metabolism of diabetes, especially type 2 diabetes (T2D), and cancer, including their abnormal glucose and amino acid metabolism, the contribution of hyperglycemia to oncogenic mutation, and the contribution of hyperinsulinemia to cancer progression. Investigating the metabolic interplay between diabetes and cancer in an effort to exploit this connection for cancer treatment has the potential to significantly improve clinical efficacy.
https://pubmed.ncbi.nlm.nih.gov/34014546/
head to RG but put χονδρική in stage 4
https://www.mdanderson.org/publications/focused-on-health/Diabetes-and-cancer.h26Z1591413.html
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2890380/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616213/
https://www.diabetes.org.uk/diabetes-the-basics/related-conditions/diabetes-and-cancer
https://www.frontiersin.org/articles/10.3389/fendo.2022.800995/full
https://www.cityofhope.org/cancer-and-diabetes-more-connections-than-you-think
https://diabetes.org/tools-support/diabetes-prevention/diabetes-and-cancer
https://www.cancer.net/navigating-cancer-care/when-cancer-not-your-only-health-concern/managing-diabetes-when-you-have-cancer
https://www.mdpi.com/2072-6694/13/22/5735/htm
https://www.cancercenter.com/community/blog/2021/05/diabetes-cancer
https://www.cdc.gov/diabetes/library/features/diabetes_cancer.html
https://www.macmillan.org.uk/cancer-information-and-support/treatment/coping-with-treatment/diabetes
https://www.macmillan.org.uk/cancer-information-and-support/advanced-cancer/diabetes
https://pancan.org/facing-pancreatic-cancer/living-with-pancreatic-cancer/diet-and-nutrition/diabetes-and-pancreatic-cancer/
https://www.cancer.gov/news-events/cancer-currents-blog/2021/pancreatic-cancer-diabetes-early-detection
https://batonrougeclinic.com/does-having-diabetes-increase-your-cancer-risk/
https://diabetologia-journal.org/2023/01/25/uk-study-shows-increased-cancer-mortality-in-people-with-type-2-diabetes/
https://diatribe.org/what-do-when-it%E2%80%99s-diabetes-and-cancer
https://www.pancreaticcancer.org.uk/information/managing-symptoms-and-side-effects/diabetes-with-pancreatic-cancer/
https://www.diabetes.co.uk/diabetes-complications/diabetes-and-cancer.html
https://www.cancerresearchuk.org/about-cancer/treatment/chemotherapy/living-with/diabetes-and-chemotherapy
https://cancerci.biomedcentral.com/articles/10.1186/s12935-021-02040-5
https://diabetesjournals.org/care/article/45/6/e105/146857/Incidence-of-New-Onset-Type-2-Diabetes-After
https://www.cancercouncil.com.au/cancer-information/living-well/nutrition-and-cancer/nutrition-concerns/diabetes/
https://www.diabinfo.de/en/living-with-diabetes/complications/cancer.html
https://link.springer.com/article/10.1007/s00125-022-05854-8
https://ar.iiarjournals.org/content/42/4/1899
https://today.ucsd.edu/story/the-paired-perils-of-breast-cancer-and-diabetes
https://www.hindawi.com/journals/isrn/2013/583786/
https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(22)00527-8/fulltext
http://www.bccancer.bc.ca/nutrition-site/Documents/Patient%20Education/Managing_Diabetes_During_Cancer_Treatment.pdf
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0276913
https://jamanetwork.com/journals/jamaoncology/article-abstract/2794807
https://www.nature.com/articles/s41416-022-01758-x
https://data.worldbank.org/indicator/SH.DYN.NCOM.ZS
https://pro.endocrineweb.com/type-1-diabetes/type-1-diabetes-linked-increased-risk-some-types-cancer
https://www.helmholtz-munich.de/en/idc
Β. ΣΥΝΝΟΣΗΡΟΤΗΕΣ/ΕΠΙΠΛΟΚΕΣ
- υποθυρεοειδι, lichen, k λοιπά προσεγμενα: check last chimp, παρκινσον, ινομυωμα, ωχρα, : αλλά να είναι καλα καμωμένες, όχι μια παράγραφο όπως έκανα με ωχρά
Γ. ΑΝΤΙΜΕΤΩΠΙΣΗ
ΒΕΛΟW FOR ALL DXN, GREG, Ggr, Gen, Pub, food groups from 16, foods from 16,
ΦΥΤΙΚΑ
ΜΑΝΙΤΑΡΙΑ
ΦΑΡΜΑΚΕΥΤΙΚΑ ΜΑΝΙΤΑΡΙΑ
ΓΑΝΟΔΕΡΜΑ
ΤΙ ΕΙΝΑΙ
ΙΣΤΟΡΙΚΑ
ΟΝΟΜΑΤΑ
ΙΔΙΟΤΗΤΕΣ
ΠΡΟΚΛΙΝΙΚΕΣ
ΚΛΙΝΙΚΑ => όσες όχι αποτελεσμα: δοσολογία, split, άδειο στομαχι
ΠΕΡΙΛΗΨΗ
PROMO
GAD 1000-1000
μία μετα 2021
Pooled prevalence (PP) of oral cancer in patients with diabetic was 0.25% (95% CI = 0.15-0.39)-250 per 100,000 patients with diabetes mellitus -with a greater chance of oral cancer among patients with diabetes mellitus (OR = 1.41 [95% CI = 1.10-1.81], p = .007). Patients with oral cancer and diabetes mellitus had a higher mortality than controls (HR = 2.09 [95%CI = 1.36-3.22], p = .001). Leukoplakia had a PP = 2.49% (95% CI = 1.14-4.29)-2,490 per 100,000 patients with diabetes mellitus -(OR = 4.34 [95% CI = 1.14-16.55], p = .03). A PP of 2.72 (95% CI = 1.64-4.02) was obtained for oral lichen planus among patients with diabetic -2,720 per 100,000 patients with diabetes mellitus (OR = 1.87 [95% CI = 1.37-2.57], p < .001). A low PP was estimated for erythroplakia (0.02%[95%CI = 0.00-0.12]-20 per 100,000 patients with diabetes mellitus. In conclusion, patients with diabetes mellitus have a higher prevalence and greater chance of oral cancer and OPMD development in comparison with non-diabetic patients. In addition, patients with oral cancer suffering from diabetes mellitus have a higher mortality compared to non-diabetic patients with oral cancer
https://pubmed.ncbi.nlm.nih.gov/31994293/
rev 2016
Recent studies suggest that there is also association between cancer incidence and anti-diabetic medications. It was observed that some medications decrease the risk of carcinogenesis and some increase that risk. The majority of studies concern metformin, a drug of choice in type 2 diabetes mellitus, and its anti-neoplastic and tumor-suppressing activity. The positive effect of metformin was found in numerous researches investigating breast, pancreas, liver, colon, ovaries and prostate tumors.Because a variety of studies have suggested that diabetes mellitus and cancer are frequently coexisting diseases, recently published studies try to explain the influence of diabetes mellitus and anti-diabetic medications on carcinogenesis in different organs.We present the review of the latest studies investigating the association between both diabetes mellitus and anti-diabetic medications and cancer incidence and prognosis.Particularly we highlight the problem of concomitant head and neck cancers in diabetics, rarely analysed and often omitted in studies
https://pubmed.ncbi.nlm.nih.gov/27219686/
rev 20
Obesity and diabetes have both been associated with an increased risk of cancer. In the face of increasing obesity and diabetes rates worldwide, this is a worrying trend for cancer rates. Factors such as hyperinsulinemia, chronic inflammation, antihyperglycemic medications, and shared risk factors have all been identified as potential mechanisms underlying the relationship. The most common obesity- and diabetes-related cancers are endometrial, colorectal, and postmenopausal breast cancers. In this review, we summarize the existing evidence that describes the complex relationship between obesity, diabetes, and cancer, focusing on epidemiological and pathophysiological evidence, and also reviewing the role of antihyperglycemic agents, novel research approaches such as Mendelian Randomization, and the methodological limitations of existing research. In addition, we also describe the bidirectional relationship between diabetes and cancer with a review of the evidence summarizing the risk of diabetes following cancer treatment. We conclude this review by providing clinical implications that are relevant for caring for patients with obesity, diabetes, and cancer and provide recommendations for improving both clinical care and research for patients with these conditions.
https://pubmed.ncbi.nlm.nih.gov/31722374/
Many observations suggest that obesity and diabetes are associated with an increased risk of developing several types of cancers, including liver, pancreatic, endometrial, colorectal, and post-menopausal breast cancer
Epidemiologically, individuals with obesity and diabetes are susceptible to an increased risk as well as a greater mortality rates for several types of cancers, such as endometrial, liver, pancreatic, colorectal, and breast cancer
Growing epidemiological evidence is hinting at a causal link between obesity, diabetes, and cancer
T2DM AND CANCER DEVELOPMENT Diabetes mellitus (DM) is one of the most prevalent chronic metabolic disorder characterized by hyperglycemia [3]. Dysfunction of pancreatic insulin-producing β-cells and insulin resistance mainly leads to hyperglycemia, resulting in increased risk of T2DM development [93]. T2DM is most common form of DM, which accounts for around 90% of all cases of diabetes [93]. T2DM may be associated with increased risk, accelerated progression and greater mortality rates of several types of cancer such as liver, pancreatic, endometrial, colorectal, and breast cancer [3,94,95]. Anti-diabetic drugs, such as metformin, have recently attracted considerable interest and opened a promising avenue of research that has the potential for the treatment of breast and colorectal cancers due to their proposed anti-cancer properties [95-98]. In the following section, we discuss the various mechanism by which metabolic disturbances in T2DM, such as dyslipidemia, hyperinsulinemia, and hyperglycemia, may lead to the development of breast cancer.
CONCLUSIONS The growing prevalence of obesity and diabetes are closely linked to an increased incidence and mortality of many types of cancer [2-4,9,56,94]. The multiple metabolic factors and disorders linking obesity and T2DM with cancer that are broadly discussed in this review may be important for determining the therapeutic potential of cancer treatment. Altered adipose tissue metabolism in obesity results in altered levels of multiple factors, such as hormones, adipokines, inflammatory cytokines, growth factors, enzymes, and free fatty acids to help cancer cells satisfy their metabolic and energy demands [7,13,24]. Adipocytes also acquire phenotypic changes through multiple bioactive factors released by surrounding cancer cells, resulting in significantly increased secretion of many metabolic substrates [30,78,87]. This adipocyte/cancer cell crosstalk within the tumor microenvironment leads to further morphological and functional alterations of both cell types, which is gradually being recognized as an integral part of cancer development and progression. However, many important questions remain regarding the molecular fingerprint and the biological roles of such a crosstalk in promoting cancer development and progression. Therefore, (1) a more in-depth understanding of how adipocytes interact with tumor cells and contribute to cancer development and progression is required; (2) identification of specific targets that can serve as promising avenues to limit tumor proliferation need to be identified; (3) determination of new strategies to block this interaction could be an effective/attractive therapeutic strategy in the treatment of cancers. T2DM is the most common form of diabetes that appears to be associated with an increased risk of several types of cancer due to its associations with multiple metabolic disturbances [94,95]. Various metabolic disturbances involved in the development of diabetes, such as dyslipidemia and hyperinsulinemia, are well established to lead to the development of a cancer-conducive microenvironment. Based on these observations, a series of studies suggest that the use of anti-diabetic drugs, e.g., metformin, may have the potential to reduce the cancer incidence and/or mortality in diabetic patients. Mechanistically, metformin reduces the circulating levels of insulin and IGF-1, thus inhibiting the mTOR pathway and subsequent cancer cell proliferation [128]. Given the potential of metformin for cancer therapy, metformin has attracted increased attention and opened new avenues in cancer treatment due to their proposed anti-cancer properties. In contrast, a recent a population-based cohort study indicated that metformin use was not associated with significantly decreased risk of cancer among patients with diabetes [129-131]. Based on large population-based cohort studies, further insights into the potential utility of metformin will be required to evaluate the effect of metformin therapy in cancer incidence.
https://europepmc.org/article/MED/34847640
Type-2-diabetes (T2D) increases the risk for several cancers and cancer has become the major cause of death of T2D-patients. T2D is causally associated with colorectal, pancreatic, gallbladder, biliary, hepatocellular, gastric, esophageal, oral, breast, endometrial, ovary, kidney and thyroid cancers as well as leukemias. When T2D goes along with tobacco smoking, alcohol use, physical inactivity, excess body weight, poor diet, familial risk or certain chronic infections, the cumulative cancer risk rises, and T2D-patients often suffer from cancer disease at younger age. T2D-patients should be encouraged to join cancer screening programmes even at younger age than the average non-diabetic population.
https://pubmed.ncbi.nlm.nih.gov/34521128/
Peripheral insulin resistance and hyperinsulinemia are the predominant diabetic traits in pancreatic cancer.
The causal relationship between diabetes and pancreatic cancer remains an intriguing but unanswered question. Since diabetes often precedes pancreatic cancer, it is regarded as a potential risk factor for malignancy. On the other hand, there remains the possibility that pancreatic cancer secretes diabetogenic factors. Regardless of how the science ultimately illuminates this issue, there is increasing interest in utilizing screening for diabetes to aid early detection of pancreatic tumor lesions. Therefore, in this issue of Pancreatology and the Web, we explore the topic of diabetes to keep us alert to this very important association, even if we study diseases of the exocrine pancreas
https://pubmed.ncbi.nlm.nih.gov/19299909/
Case presentation: We report the case of a 50-year-old man with a diagnosis of type 2 diabetes mellitus who-despite appropriate pharmacotherapy-developed worsening hyperglycemia. Further investigation revealed the presence of metastatic pancreatic cancer.
Discussion: Although an association between pancreatic cancer and diabetes has been noted widely in the gastroenterology, oncology, and endocrine literature, a paucity of primary care literature on the topic exists. Features of predominant insulin deficiency and new onset of diabetes in a patient without family history of type 2 diabetes should raise suspicion for undetected/early-stage pancreatic cancer.
Conclusions: This case highlights the importance of considering all possible pathophysiologic etiologies when a patient has a new diagnosis of diabetes. Clinicians should consider the possibility of pancreatic cancer in patients with new-onset diabetes mellitus, especially when features not characteristic of type 2 diabetes are present. Understanding the relationship between diabetes and pancreatic cancer has the potential to improve early detection of pancreatic cancer and can provide an opportunity for early treatment and improved survival.
https://pubmed.ncbi.nlm.nih.gov/30407768/
Diabetic mastopathy is a recently described pathological entity. Little is known about this benign condition. It usually occurs in young patients with type 1 diabetes, or having an autoimmune disorders. Clinically, this mastopathy simulates a breast cancer. Graphic tests are not very informative. The diagnosis is histological. Through a case of diabetic mastopathy occurring in a patient with diabetes on insulin for 16 years and carries multiple degenerative complications, we recall the clinical, radiological and outcome of this disease.
https://pubmed.ncbi.nlm.nih.gov/20971584/
Diabetes mellitus, commonly known as diabetes, and cancer are two of the most common diseases plaguing the world today. According to the Centers for Disease Control and Prevention (CDC), there are currently more than 20 million people with diabetes in the United States [1]. According to the International Agency for Research on Cancer (IARC), there were around 18 million people diagnosed with cancer, with approximately ten million deaths globally in 2018 [2]. Given the prevalence and deadliness of diabetes and cancer, these two diseases have long been the focus of many researchers with the goal of improving treatment outcomes. While diabetes and cancer may seem to be two very different diseases at first glance, they share several similarities, especially regarding their metabolic characteristics. This chapter discusses the similarities and relationships between the metabolism of diabetes, especially type 2 diabetes (T2D), and cancer, including their abnormal glucose and amino acid metabolism, the contribution of hyperglycemia to oncogenic mutation, and the contribution of hyperinsulinemia to cancer progression. Investigating the metabolic interplay between diabetes and cancer in an effort to exploit this connection for cancer treatment has the potential to significantly improve clinical efficacy.
https://pubmed.ncbi.nlm.nih.gov/34014546/
head to RG but put χονδρική in stage 4
https://www.mdanderson.org/publications/focused-on-health/Diabetes-and-cancer.h26Z1591413.html
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2890380/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616213/
https://www.diabetes.org.uk/diabetes-the-basics/related-conditions/diabetes-and-cancer
https://www.frontiersin.org/articles/10.3389/fendo.2022.800995/full
https://www.cityofhope.org/cancer-and-diabetes-more-connections-than-you-think
https://diabetes.org/tools-support/diabetes-prevention/diabetes-and-cancer
https://www.cancer.net/navigating-cancer-care/when-cancer-not-your-only-health-concern/managing-diabetes-when-you-have-cancer
https://www.mdpi.com/2072-6694/13/22/5735/htm
https://www.cancercenter.com/community/blog/2021/05/diabetes-cancer
https://www.cdc.gov/diabetes/library/features/diabetes_cancer.html
https://www.macmillan.org.uk/cancer-information-and-support/treatment/coping-with-treatment/diabetes
https://www.macmillan.org.uk/cancer-information-and-support/advanced-cancer/diabetes
https://pancan.org/facing-pancreatic-cancer/living-with-pancreatic-cancer/diet-and-nutrition/diabetes-and-pancreatic-cancer/
https://www.cancer.gov/news-events/cancer-currents-blog/2021/pancreatic-cancer-diabetes-early-detection
https://batonrougeclinic.com/does-having-diabetes-increase-your-cancer-risk/
https://diabetologia-journal.org/2023/01/25/uk-study-shows-increased-cancer-mortality-in-people-with-type-2-diabetes/
https://diatribe.org/what-do-when-it%E2%80%99s-diabetes-and-cancer
https://www.pancreaticcancer.org.uk/information/managing-symptoms-and-side-effects/diabetes-with-pancreatic-cancer/
https://www.diabetes.co.uk/diabetes-complications/diabetes-and-cancer.html
https://www.cancerresearchuk.org/about-cancer/treatment/chemotherapy/living-with/diabetes-and-chemotherapy
https://cancerci.biomedcentral.com/articles/10.1186/s12935-021-02040-5
https://diabetesjournals.org/care/article/45/6/e105/146857/Incidence-of-New-Onset-Type-2-Diabetes-After
https://www.cancercouncil.com.au/cancer-information/living-well/nutrition-and-cancer/nutrition-concerns/diabetes/
https://www.diabinfo.de/en/living-with-diabetes/complications/cancer.html
https://link.springer.com/article/10.1007/s00125-022-05854-8
https://ar.iiarjournals.org/content/42/4/1899
https://today.ucsd.edu/story/the-paired-perils-of-breast-cancer-and-diabetes
https://www.hindawi.com/journals/isrn/2013/583786/
https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(22)00527-8/fulltext
http://www.bccancer.bc.ca/nutrition-site/Documents/Patient%20Education/Managing_Diabetes_During_Cancer_Treatment.pdf
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0276913
https://jamanetwork.com/journals/jamaoncology/article-abstract/2794807
https://www.nature.com/articles/s41416-022-01758-x
https://data.worldbank.org/indicator/SH.DYN.NCOM.ZS
https://pro.endocrineweb.com/type-1-diabetes/type-1-diabetes-linked-increased-risk-some-types-cancer
https://www.helmholtz-munich.de/en/idc
Β. ΣΥΝΝΟΣΗΡΟΤΗΕΣ/ΕΠΙΠΛΟΚΕΣ
- υποθυρεοειδι, lichen, k λοιπά προσεγμενα: check last chimp, παρκινσον, ινομυωμα, ωχρα, : αλλά να είναι καλα καμωμένες, όχι μια παράγραφο όπως έκανα με ωχρά
Γ. ΑΝΤΙΜΕΤΩΠΙΣΗ
ΒΕΛΟW FOR ALL DXN, GREG, Ggr, Gen, Pub, food groups from 16, foods from 16,
ΦΥΤΙΚΑ
ΜΑΝΙΤΑΡΙΑ
ΦΑΡΜΑΚΕΥΤΙΚΑ ΜΑΝΙΤΑΡΙΑ
ΓΑΝΟΔΕΡΜΑ
ΤΙ ΕΙΝΑΙ
ΙΣΤΟΡΙΚΑ
ΟΝΟΜΑΤΑ
ΙΔΙΟΤΗΤΕΣ
ΠΡΟΚΛΙΝΙΚΕΣ
ΚΛΙΝΙΚΑ => όσες όχι αποτελεσμα: δοσολογία, split, άδειο στομαχι
ΠΕΡΙΛΗΨΗ
PROMO
GAD 1000-1000
3. - 0: (poria cocos OR fuling OR fu ling) AND
4. - 0,01: (andrographis OR andrographis paniculata OR andrographolide) AND
6. - 1,5: (goji berries OR goji berry OR wolfberry OR Lycium barbarum OR Lycium chinense OR Gou Qi Zi OR Fructus lycii) AND
7. - 0,7: (black cumin OR nigella sativa) AND
8. - 0,04: (hericium OR lion's mane) AND
9. - 0,02: (cordyceps OR cordycepin) AND
10. - 1,7: Hibiscus AND [cs, ιβίσκος (DXN ROS L Powder 30 Grams Hibiscus Sabdariffa)
4. - 0,01: (andrographis OR andrographis paniculata OR andrographolide) AND
6. - 1,5: (goji berries OR goji berry OR wolfberry OR Lycium barbarum OR Lycium chinense OR Gou Qi Zi OR Fructus lycii) AND
7. - 0,7: (black cumin OR nigella sativa) AND
8. - 0,04: (hericium OR lion's mane) AND
9. - 0,02: (cordyceps OR cordycepin) AND
10. - 1,7: Hibiscus AND [cs, ιβίσκος (DXN ROS L Powder 30 Grams Hibiscus Sabdariffa)
do RM
1.000 + 1.000 κ μετά focus on build below kwords
rot: 1 greg video + 3 diab url σύμφωνα με Ggr terms + MM τι do με γανόδερμα, κορντισεπς, ανδροραφίς, μαυρο κύμινο
βρωμη διαβητησ 10-100 / 0-10
βρωμη και διαβητησ 10-100 / 0-10
βρωμη και σακχαρωδησ διαβητησ 10-100 / 0-10
βρώμη διαβήτη 0-10/ -
νιφαδεσ βρωμησ και διαβητησ 10-100 / -
συνταγεσ με βρωμη για διαβητικουσ 10-100 / 0-10 => δω Greger comments
Συνταγεσ με βρωμη για βραδινο 100-1k / 90
https://nutritionfacts.org/video/is-oatmeal-good-for-people-with-diabetes/
https://nutritionfacts.org/video/how-does-oatmeal-help-with-blood-sugars/
https://nutritionfacts.org/video/oatmeal-diet-put-to-the-test-for-diabetes-treatment/
διαβητησ
σακχαρώδησ διαβήτησ τύπου 2
ζαχαρωδησ διαβητησ τυπου 2
ζαχαροδιαβητησ τυπου 2
*διαβήτη τύπου 1*
Gsugg8
NAs:
1. all below terms, in each subgoup, περαιτερω ομαδοποίηση
2. all below terms: check their Gsugg + Gabc ώστε σχετικό url
3. redo above in Gen + Pub
ΑΝΤΙΜΕΤΩΠΙΣΗ
διαβητησ αντιμετωπιση 10-100 / 0-10
διαβητησ τυπου 2 αντιμετωπιση 10-100 / 0-10
σακχαρώδησ διαβήτησ αντιμετωπιση 10-100 / 0-10
αντιμετωπιση διαβητη τυπου 2 0-10 / 0-10
διαβητησ φυσικη αντιμετωπιση 10-100 / 10
διαβητησ εναλλακτικη θεραπεια 0-10 / 0-10
ομοιοπαθητικη και διαβητησ τυπου 2 10-100 / - => τα δίνω άλλα μετά αναφέρω και τα δικά μου
φυσικη θεραπεια διαβητη 10-100 / -
διαβητης θεραπεια 0-10 / 0-10
διαβήτησ τύπου 2 θεραπεια 10-100 / 10
διαβητησ 2 θεραπεια 10-100 / 0-10
θεραπεια διαβητη τυπου 2 10-100 / 10
ο διαβητησ τυπου 2 θεραπευεται 10-100 / -
Οριστικη θεραπεια διαβητη τυπου 2 100-1k / 400
σακχαρώδησ διαβήτησ θεραπεια 10-100 / 0-10
σακχαρώδησ διαβήτησ τύπου 2 θεραπεια 10-100 / 10
αντιμετωπιση διαβητη χωρισ φαρμακα 0-10 / 0-10
διαβητησ θεραπεια χωρισ φαρμακα 10-100 / 0-10
διαβήτησ τύπου 2 θεραπεια χωρισ φαρμακα 0-10 / -
διαβητησ χωρισ φαρμακα 0-10 / 0-10
θεραπεια διαβητη τυπου 2 χωρισ φαρμακα 100-1k / 150 /// θεραπεια διαβητη τυπου 2 χωρις φαρμακα
ρυθμιση διαβητη χωρισ φαρμακα 10-100 / 20
Το καλυτερο συμπληρωμα για διαβητη 100-1k / 250
πολυβιταμινες για διαβητικους 10-100 / 10
Τα τελευταια νεα για το διαβητη 10-100 / -
Τελευταια νεα για διαβητη τυπου 2 10-100 / 30 / latest news for diabetes type 2
ΔΙΑΤΡΟΦΗ => μελέτες που δείχνουν πλήρη ίαση
διαβητης διατροφη
διαβήτησ και διατροφή
διαβήτησ τύπου 2 διατροφή
διαβήτησ τύπου 2 και διατροφη
σακχαρώδησ διαβήτησ τύπου 2 διατροφη
ζαχαρωδησ διαβητησ τυπου 2 διατροφη
εβδομαδιαια διαιτα για διαβητικους
γρηγορη διαιτα για διαβητικους
διαιτα για διαβητικους για δεκα κιλα
διαιτα για διαβητικους τυπου 2
διαβητησ διαιτολογιο
διαβητησ τυπου 2 διαιτα
διαβητησ απωλεια βαρουσ
διαβητησ τυπου 2 απωλεια βαρουσ
ΑΛΚΟΟΛ
διαβητησ αλκοολ
διαβητησ και αλκοολ
διαβητησ τυπου 2 και αλκοολ
ΒΟΤΑΝΑ
διαβητησ βοτανα
διαβητησ βοτανο
διαβήτησ τύπου 2 βοτανα
ΒΙΤΑΜΙΝΕΣ
διαβητησ και βιταμινεσ
διαβητησ και βιταμινη d
διαβητησ και βιταμινη β12
Β12 και διαβητησ
Μετφορμινη και β12/
μαγνησιο και διαβητης /
Βιταμινεσ για διαβητικουσ
απαραιτητεσ βιταμινεσ για διαβητικουσ
βιταμινεσ καταλληλεσ για διαβητικουσ
ΤΡΟΦΕΣ
απαγορευμενες τροφες για το ζαχαρο
χαρουπι διαβητησ
χαρουπάλευρο διαβητησ
χαρουπομελο διαβητησ
διαβητησ διατροφη μελι
διαβητησ ζαχαρη
ζαχαρινη διαβητησ
διαβητησ διατροφη ξηροι καρποι
Καστανο διαβητησ 10-100 / 0-10
καστανο και διαβητησ 10-100 / 0-10
ηλιοσποροσ διαβητησ
λιναροσποροσ διαβητησ
διαβητησ λαχανικα
λαχανο διαβητησ
διαβητησ ντοματα
διαβητησ φρουτα
διαβητησ τυπου 2 και φρουτα
λωτοσ διαβητησ
λεμονι διαβητησ
διαβητησ μπανανα
ροδι διαβητησ
ροδακινο διαβητησ
χουρμαδεσ διαβητησ
διαβητησ οσπρια
ρεβυθια διαβητησ
διαβητησ φακεσ
διαβητησ φασολια
λαγοκοιμηθια διαβητησ
ριγανη διαβητησ
χαμομηλι διαβητησ
διαβητησ νερο
ξυδι διαβητησ
διαβητησ ρυζι
ρυζογκοφρετα διαβητησ
καστανο ρυζι διαβητησ
χαλβασ διαβητησ
διαβητησ ψωμι
διαβήτησ και μαύρο ψωμί
διαβητησ πρωινο
διαβητησ ψαρια
κοκκινο κρεασ, επεηερασμενο κρεας, γαλακτομικα
ΑΣΚΗΣΗ
διαβητησ τυπου 2 ασκηση / διαβητησ τυπου 2 και ασκηση
ΕΠΙΠΛΟΚΕΣ
διαβητησ τυπου 2 προσδοκιμο ζωησ /
διαβήτησ τύπου 2 επιπλοκεσ
ΑΙΤΙΑ
διαβητησ τυπου 2 αιτια
1.000 + 1.000 κ μετά focus on build below kwords
rot: 1 greg video + 3 diab url σύμφωνα με Ggr terms + MM τι do με γανόδερμα, κορντισεπς, ανδροραφίς, μαυρο κύμινο
βρωμη διαβητησ 10-100 / 0-10
βρωμη και διαβητησ 10-100 / 0-10
βρωμη και σακχαρωδησ διαβητησ 10-100 / 0-10
βρώμη διαβήτη 0-10/ -
νιφαδεσ βρωμησ και διαβητησ 10-100 / -
συνταγεσ με βρωμη για διαβητικουσ 10-100 / 0-10 => δω Greger comments
Συνταγεσ με βρωμη για βραδινο 100-1k / 90
https://nutritionfacts.org/video/is-oatmeal-good-for-people-with-diabetes/
https://nutritionfacts.org/video/how-does-oatmeal-help-with-blood-sugars/
https://nutritionfacts.org/video/oatmeal-diet-put-to-the-test-for-diabetes-treatment/
διαβητησ
σακχαρώδησ διαβήτησ τύπου 2
ζαχαρωδησ διαβητησ τυπου 2
ζαχαροδιαβητησ τυπου 2
*διαβήτη τύπου 1*
Gsugg8
NAs:
1. all below terms, in each subgoup, περαιτερω ομαδοποίηση
2. all below terms: check their Gsugg + Gabc ώστε σχετικό url
3. redo above in Gen + Pub
ΑΝΤΙΜΕΤΩΠΙΣΗ
διαβητησ αντιμετωπιση 10-100 / 0-10
διαβητησ τυπου 2 αντιμετωπιση 10-100 / 0-10
σακχαρώδησ διαβήτησ αντιμετωπιση 10-100 / 0-10
αντιμετωπιση διαβητη τυπου 2 0-10 / 0-10
διαβητησ φυσικη αντιμετωπιση 10-100 / 10
διαβητησ εναλλακτικη θεραπεια 0-10 / 0-10
ομοιοπαθητικη και διαβητησ τυπου 2 10-100 / - => τα δίνω άλλα μετά αναφέρω και τα δικά μου
φυσικη θεραπεια διαβητη 10-100 / -
διαβητης θεραπεια 0-10 / 0-10
διαβήτησ τύπου 2 θεραπεια 10-100 / 10
διαβητησ 2 θεραπεια 10-100 / 0-10
θεραπεια διαβητη τυπου 2 10-100 / 10
ο διαβητησ τυπου 2 θεραπευεται 10-100 / -
Οριστικη θεραπεια διαβητη τυπου 2 100-1k / 400
σακχαρώδησ διαβήτησ θεραπεια 10-100 / 0-10
σακχαρώδησ διαβήτησ τύπου 2 θεραπεια 10-100 / 10
αντιμετωπιση διαβητη χωρισ φαρμακα 0-10 / 0-10
διαβητησ θεραπεια χωρισ φαρμακα 10-100 / 0-10
διαβήτησ τύπου 2 θεραπεια χωρισ φαρμακα 0-10 / -
διαβητησ χωρισ φαρμακα 0-10 / 0-10
θεραπεια διαβητη τυπου 2 χωρισ φαρμακα 100-1k / 150 /// θεραπεια διαβητη τυπου 2 χωρις φαρμακα
ρυθμιση διαβητη χωρισ φαρμακα 10-100 / 20
Το καλυτερο συμπληρωμα για διαβητη 100-1k / 250
πολυβιταμινες για διαβητικους 10-100 / 10
Τα τελευταια νεα για το διαβητη 10-100 / -
Τελευταια νεα για διαβητη τυπου 2 10-100 / 30 / latest news for diabetes type 2
ΔΙΑΤΡΟΦΗ => μελέτες που δείχνουν πλήρη ίαση
διαβητης διατροφη
διαβήτησ και διατροφή
διαβήτησ τύπου 2 διατροφή
διαβήτησ τύπου 2 και διατροφη
σακχαρώδησ διαβήτησ τύπου 2 διατροφη
ζαχαρωδησ διαβητησ τυπου 2 διατροφη
εβδομαδιαια διαιτα για διαβητικους
γρηγορη διαιτα για διαβητικους
διαιτα για διαβητικους για δεκα κιλα
διαιτα για διαβητικους τυπου 2
διαβητησ διαιτολογιο
διαβητησ τυπου 2 διαιτα
διαβητησ απωλεια βαρουσ
διαβητησ τυπου 2 απωλεια βαρουσ
ΑΛΚΟΟΛ
διαβητησ αλκοολ
διαβητησ και αλκοολ
διαβητησ τυπου 2 και αλκοολ
ΒΟΤΑΝΑ
διαβητησ βοτανα
διαβητησ βοτανο
διαβήτησ τύπου 2 βοτανα
ΒΙΤΑΜΙΝΕΣ
διαβητησ και βιταμινεσ
διαβητησ και βιταμινη d
διαβητησ και βιταμινη β12
Β12 και διαβητησ
Μετφορμινη και β12/
μαγνησιο και διαβητης /
Βιταμινεσ για διαβητικουσ
απαραιτητεσ βιταμινεσ για διαβητικουσ
βιταμινεσ καταλληλεσ για διαβητικουσ
ΤΡΟΦΕΣ
απαγορευμενες τροφες για το ζαχαρο
χαρουπι διαβητησ
χαρουπάλευρο διαβητησ
χαρουπομελο διαβητησ
διαβητησ διατροφη μελι
διαβητησ ζαχαρη
ζαχαρινη διαβητησ
διαβητησ διατροφη ξηροι καρποι
Καστανο διαβητησ 10-100 / 0-10
καστανο και διαβητησ 10-100 / 0-10
ηλιοσποροσ διαβητησ
λιναροσποροσ διαβητησ
διαβητησ λαχανικα
λαχανο διαβητησ
διαβητησ ντοματα
διαβητησ φρουτα
διαβητησ τυπου 2 και φρουτα
λωτοσ διαβητησ
λεμονι διαβητησ
διαβητησ μπανανα
ροδι διαβητησ
ροδακινο διαβητησ
χουρμαδεσ διαβητησ
διαβητησ οσπρια
ρεβυθια διαβητησ
διαβητησ φακεσ
διαβητησ φασολια
λαγοκοιμηθια διαβητησ
ριγανη διαβητησ
χαμομηλι διαβητησ
διαβητησ νερο
ξυδι διαβητησ
διαβητησ ρυζι
ρυζογκοφρετα διαβητησ
καστανο ρυζι διαβητησ
χαλβασ διαβητησ
διαβητησ ψωμι
διαβήτησ και μαύρο ψωμί
διαβητησ πρωινο
διαβητησ ψαρια
κοκκινο κρεασ, επεηερασμενο κρεας, γαλακτομικα
ΑΣΚΗΣΗ
διαβητησ τυπου 2 ασκηση / διαβητησ τυπου 2 και ασκηση
ΕΠΙΠΛΟΚΕΣ
διαβητησ τυπου 2 προσδοκιμο ζωησ /
διαβήτησ τύπου 2 επιπλοκεσ
ΑΙΤΙΑ
διαβητησ τυπου 2 αιτια
